Last updated on December 2018

Study of Ibrutinib and Rituximab in Treatment Na ve Follicular Lymphoma


Brief description of study

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment nave subjects with follicular lymphoma.

Clinical Study Identifier: NCT02947347

Contact Investigators or Research Sites near you

Start Over

CHU Bordeaux

Pessac, France
8.81miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.